<DOC>
	<DOCNO>NCT01690169</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability pharmacokinetics ( exposure trial drug body ) single dose NNC0113-0987 healthy male subject .</brief_summary>
	<brief_title>Investigation Safety , Tolerability , Pharmacokinetics Single Doses NNC0113-0987 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male subject good general health judge investigator , base medical history , physical examination include 12lead electrocardiogram ( ECG ) , vital sign , blood assessment screen visit Body mass index ( BMI ) equal 18.5 30 kg/m^ 2 Male subject sexually active surgically sterilise , whose partner unwilling use two different form effective contraception , one barrier method ( e.g. , condom spermicidal foam/gel/film/cream ) duration trial 12 week follow last dose trial medication Participation another trial within 90 day prior screen Subjects history presence cancer , diabetes , clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal ( include gastroesophageal reflux disease irritable bowel syndrome ) , endocrinological , haematological , dermatological , venereal , neurological , psychiatric disease major disorder might impact current trial , judge investigator Subjects know hepatitis carrier Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody , positive result test Human Immunodeficiency Virus ( HIV ) antibodies History acute idiopathic chronic pancreatitis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>